Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Supernus Pharmaceuticals Inc Receives Three Years of Market Exclusivity for Oxtellar XR


Monday, 19 Nov 2012 07:00am EST 

Supernus Pharmaceuticals Inc announced that it has received confirmation from the Food and Drug Administration (the FDA) that Oxtellar XR has been granted three years of market exclusivity. Supernus received approval from the FDA on October 19, 2012 for Oxtellar XR, a once-daily extended release antiepileptic drug indicated for adjunctive therapy in the treatment of partial seizures in adults and in children Six to 17 years of age. 

Company Quote

8.96
0.11 +1.24%
26 Aug 2014